Expansion30 Jun 2026, 05:50 pm
Aarti Pharmalabs Expands Capacity with New Manufacturing Block
AI Summary
Aarti Pharmalabs Limited has inaugurated a new state-of-the-art manufacturing block at its Tarapur Unit 5 in Maharashtra. This expansion adds 3600 TPA capacity for Xanthine derivatives, bringing the total to 9600 TPA and positioning the company among the top three global manufacturers in this segment. Trial production has commenced, with full utilization expected in the coming quarters. The new facility aims to strengthen production capabilities and cater to larger customer needs.
Key Highlights
- New manufacturing block inaugurated at Tarapur Unit 5.
- Increases Xanthine derivatives capacity by 3600 TPA to 9600 TPA.
- Positions Aarti Pharmalabs among top 3 global Xanthine derivatives producers.
- Trial production initiated, full ramp-up expected in next few quarters.
Price Impact
More from AARTIPHARM